483 related articles for article (PubMed ID: 27445468)
1. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
[TBL] [Abstract][Full Text] [Related]
2. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
3. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
4. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Zheng J; Zhong N; Newlands A; Church A; Goh AH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
8. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH
Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889
[TBL] [Abstract][Full Text] [Related]
9. The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
12. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
[TBL] [Abstract][Full Text] [Related]
13. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
14. Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β
Naya IP; Tombs L; Lipson DA; Compton C
Adv Ther; 2018 Oct; 35(10):1626-1638. PubMed ID: 30191464
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH
Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline COPD symptom severity on the benefit from dual
Vogelmeier CF; Kerwin EM; Bjermer LH; Tombs L; Jones PW; Boucot IH; Naya IP; Lipson DA; Compton C; Barnes N; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620968500. PubMed ID: 33167780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
